Phaseline

Targets › HMGCR

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase): drug programs, companies and trials

38 programs from 37 companies in 79 trials: 35 Phase 2, 21 Phase 4, 16 Phase 3, 7 Phase 1; Oncology, Cardiovascular, Neurology; next expected readout Nov 2026.

Catalyzes the conversion of (3S)-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid, the rate-limiting step in the synthesis of cholesterol and other isoprenoids, thus plays a critical role in cellular cholesterol homeostasis. HMGCR is the main target of statins, a class of cholesterol-lowering drugs. (UniProt, P04035)

Open in Phaseline: the race on HMGCR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
JW PharmaceuticalPitavastatin
HMG-CoA reductase inhibitor
HMGCRPhase 4Hypercholesterolemia; Dyslipidemias; ASCVD; Primary Prevention …Nov 2026
NYU Langone HealthAtorvastatin Calcium
HMG-CoA reductase inhibitor
HMGCRPhase 4Type 1 DiabetesJul 2027
General Hospital of Shenyang Military RegionAtorvastatin Calcium
HMG-CoA reductase inhibitor
HMGCRPhase 4Stroke, IschemicNov 2027
Jung-min AhnHigh-intensity statin
HMG-CoA reductase inhibitor
HMGCRPhase 4Cardiovascular DiseasesMar 2035
University of Colorado, DenverPravastatin
HMG-CoA reductase inhibitor
HMGCRPhase 4ADPKD–
Third Military Medical UniversitySimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 4Primary Aldosteronism–
Sherief Abd-ElsalamStatins
HMG-CoA reductase inhibitor
HMGCRPhase 3Rheumatoid ArthritisDec 2026
VA Office of Research and DevelopmentSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 3CirrhosisDec 2026
SWOG Cancer Research NetworkSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 3Bladder CarcinomaJan 2027
Lund UniversitySimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 3Graves OphthalmopathyJan 2027
AstraZenecaRosuvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 3Hypercholesterolaemia; Acute Coronary Syndromes; Coronary Artery Disease; Statin Therapy …May 2027
Ottawa Hospital Research InstituteRosuvastatin Calcium
HMG-CoA reductase inhibitor
HMGCRPhase 3Venous ThromboembolismJan 2028
Annika BergquistSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 3Primary Sclerosing CholangitisMar 2028
Northern California Institute of Research and EducationPolycap
Fixed-dose combination: aspirin (antiplatelet), simvastatin (HMG-CoA reductase inhibitor),
HMGCR, ACEPhase 3StrokeJan 2029
Universitas IndonesiaSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Triple Negative Breast CancerNov 2026
Northwestern UniversityAtorvastatin Calcium
HMG-CoA reductase inhibitor
HMGCRPhase 2Colorectal CarcinomaNov 2026
Vanderbilt UniversityLovastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Neurofibromatosis Type 1Jan 2027
Medical University of South CarolinaSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Prostate CancerMar 2027
Anna CrucetaSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Liver FibrosisMar 2027
Obafemi Awolowo University Teaching HospitalAtorvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Pulmonary Tuberculosis; Pulmonary Tuberculosis (TB)Mar 2027
National Cancer Institute, NaplesSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Adenocarcinoma of the Pancreas; Advanced or Metastatic Gastrooesophageal CarcinomaJun 2027
Inova Health Care ServicesSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2GlioblastomaSep 2027
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauPravastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Preeclampsia (PE)Nov 2027
Emory UniversityLovastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Dec 2027
The First Affiliated Hospital with Nanjing Medical UniversitySimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Metastatic Colorectal CancerDec 2027
Peter MacCallum Cancer Centre, AustraliaPravastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Radiation-associated DysphagiaOct 2028
Baylor Breast Care CenterSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Breast Cancer Stage IVDec 2028
St. Olavs HospitalAtorvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Chronic Migraine; Episodic MigraineDec 2028
M.D. Anderson Cancer CenterPravastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Lymphedema; Fibrosis SyndromeMay 2029
Institut du Cancer de Montpellier - Val d'AurellePravastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Breast CancerJan 2031
Peking University People's HospitalAtorvastatin calcium
HMG-CoA reductase inhibitor
HMGCRPhase 2Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I–
Peking University People's HospitalPravastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I–
Dow University of Health SciencesSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 2Pulpal Necrosis–
Danae Hamouda, MDSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 1Advanced Pancreatic CancerDec 2026
Children's Mercy Hospital Kansas CityPravastatin
HMG-CoA reductase inhibitor
HMGCRPhase 1Fontan CirculationMay 2027
Tongji HospitalSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 1Advanced Biliary Tract CarcinomaJan 2028
Kyushu UniversityULREA-PVS-NP
Pitavastatin encapsulated in PLGA nanoparticles; HMG-CoA reductase inhibitor delivered via
HMGCRPhase 1Retinitis Pigmentosa (RP)Jan 2028
State University of New York - Downstate Medical CenterSimvastatin
HMG-CoA reductase inhibitor
HMGCRPhase 1Pancreatic Cancer MetastaticDec 2028

Conditions

Coronary Artery Disease (5) Hypercholesterolaemia (4) Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I (3) Pulmonary Tuberculosis (3) Pulmonary Tuberculosis (TB) (3) Episodic Migraine (2) Primary Aldosteronism (2) Stroke (2) Hypercholesterolemia (2) Primary Prevention (2) Erectile Dysfunction Due to Arterial Disease (2) Ischemic Stroke (2)

Modalities

small molecule (31), mixed (3), antibody (1)

Companies

Peking University People's Hospital (2) St. Olavs Hospital (1) Institut du Cancer de Montpellier - Val d'Aurelle (1) Ottawa Hospital Research Institute (1) Third Military Medical University (1) Emory University (1) Medical University of South Carolina (1) Jung-min Ahn (1) Children's Mercy Hospital Kansas City (1) Kyushu University (1) Peter MacCallum Cancer Centre, Australia (1) Northern California Institute of Research and Education (1) University of Colorado, Denver (1) JW Pharmaceutical (1) Tongji Hospital (1) AstraZeneca (1) M.D. Anderson Cancer Center (1) Dow University of Health Sciences (1) Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) Sherief Abd-Elsalam (1)

Related targets

ACE (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.